197 related articles for article (PubMed ID: 9487235)
1. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
Perreault S; Hamilton VH; Lavoie F; Grover S
Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
[TBL] [Abstract][Full Text] [Related]
2. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.
Hamilton VH; Racicot FE; Zowall H; Coupal L; Grover SA
JAMA; 1995 Apr; 273(13):1032-8. PubMed ID: 7897787
[TBL] [Abstract][Full Text] [Related]
3. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.
Perreault S; Hamilton VH; Lavoie F; Grover S
Cardiovasc Drugs Ther; 1997 Jan; 10(6):787-94. PubMed ID: 9110123
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-RubiĆ³ P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
Malhotra HS; Goa KL
Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
[TBL] [Abstract][Full Text] [Related]
6. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.
Downs JR; Clearfield M; Weis S; Whitney E; Shapiro DR; Beere PA; Langendorfer A; Stein EA; Kruyer W; Gotto AM
JAMA; 1998 May; 279(20):1615-22. PubMed ID: 9613910
[TBL] [Abstract][Full Text] [Related]
7. Lipid-lowering for prevention of coronary heart disease: what policy now?
Ul Haq I; Ramsay LE; Pickin DM; Yeo WW; Jackson PR; Payne JN
Clin Sci (Lond); 1996 Oct; 91(4):399-413. PubMed ID: 8983865
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Martens LL; Guibert R
Clin Ther; 1994; 16(6):1052-62; discussion 1036. PubMed ID: 7697684
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease.
Goldman L; Weinstein MC; Goldman PA; Williams LW
JAMA; 1991 Mar; 265(9):1145-51. PubMed ID: 1899896
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of statins.
Huse DM; Russell MW; Miller JD; Kraemer DF; D'Agostino RB; Ellison RC; Hartz SC
Am J Cardiol; 1998 Dec; 82(11):1357-63. PubMed ID: 9856919
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the secondary prevention of cardiovascular disease: forecasting the incremental benefits of preventing coronary and cerebrovascular events.
Grover SA; Coupal L; Paquet S; Zowall H
Arch Intern Med; 1999 Mar; 159(6):593-600. PubMed ID: 10090116
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.
Prosser LA; Stinnett AA; Goldman PA; Williams LW; Hunink MG; Goldman L; Weinstein MC
Ann Intern Med; 2000 May; 132(10):769-79. PubMed ID: 10819699
[TBL] [Abstract][Full Text] [Related]
13. Combination drug therapy for hypercholesterolemia. The trade-off between cost and simplicity.
Heudebert GR; Van Ruiswyk J; Hiatt J; Schectman G
Arch Intern Med; 1993 Aug; 153(15):1828-37. PubMed ID: 8333817
[TBL] [Abstract][Full Text] [Related]
14. Comparative cost-effectiveness of HMG-CoA reductase inhibitors in secondary prevention of acute myocardial infarction.
Elliott WJ; Weir DR
Am J Health Syst Pharm; 1999 Sep; 56(17):1726-32. PubMed ID: 10512503
[TBL] [Abstract][Full Text] [Related]
15. Maximizing the cost-effectiveness of lipid-lowering therapy.
Jacobson TA; Schein JR; Williamson A; Ballantyne CM
Arch Intern Med; 1998 Oct; 158(18):1977-89. PubMed ID: 9778197
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and tolerability of low-dose pravastatin versus lovastatin in patients with hypercholesterolemia.
Strauss WE; Lapsley D; Gaziano JM
Am Heart J; 1999 Mar; 137(3):458-62. PubMed ID: 10047626
[TBL] [Abstract][Full Text] [Related]
17. Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.
Coukell AJ; Wilde MI
Pharmacoeconomics; 1998 Aug; 14(2):217-36. PubMed ID: 10186462
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population.
Pharoah PD; Hollingworth W
BMJ; 1996 Jun; 312(7044):1443-8. PubMed ID: 8664620
[TBL] [Abstract][Full Text] [Related]
19. Using the coronary artery calcium score to guide statin therapy: a cost-effectiveness analysis.
Pletcher MJ; Pignone M; Earnshaw S; McDade C; Phillips KA; Auer R; Zablotska L; Greenland P
Circ Cardiovasc Qual Outcomes; 2014 Mar; 7(2):276-84. PubMed ID: 24619318
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.
Hay JW; Sterling KL
Pharmacoeconomics; 2005; 23(2):133-41. PubMed ID: 15748088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]